Skip to main content
Toggle navigation
Menu
Overall search
Search ClinicalINFO
In affiliation with
HIV.gov
Search
Close
Main navigation
Home
About
Guidelines
Drug Database
Glossary
News
Resources
Contact Us
English
Toggle Dropdown
English
Español (Spanish)
Home
Search Results
Overall search
Search ClinicalINFO
Search Results
3361 – 3380
of
3979
Etravirine
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/etravirine
Gastrointestinal Effects
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/gastrointestinal-effects
Atazanavir (Reyataz, ATV)
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-protease-inhibitors-atazanavir-reyataz
Nelfinavir (Viracept, NFV)
https://clinicalinfo.hiv.gov/guidelines/perinatal/archived-drugs-nelfinavir-viracept
Table 14. Antiretroviral Drug Use in Pregnant People With HIV: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy | Overview
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-drug-use-pregnant-overview
Appendix B: Web-based Resources for Treating and Preventing HIV Infection
https://clinicalinfo.hiv.gov/guidelines/guidelines-caring-persons-hiv-disaster-areas/appendix-b-web-based-resources-treating-and
Dyslipidemia
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/dyslipidemia
Table 4. Common Drugs Used for Treatment of Opportunistic Infections in Children With HIV: Preparations and Major Toxicities
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table-4-common-drugs-used
Tenofovir AF
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/tenofovir-af
Modifying Antiretroviral Regimens in Children With Sustained Virologic Suppression on Antiretroviral Therapy
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/modifying-antiretroviral-regimens-children-sustained-virologic-suppression
Abacavir (Ziagen, ABC)
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nrtis-abacavir-ziagen
Rilpivirine
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/rilpivirine
Figure 1. Recommended Immunization Schedule for Children with HIV Infection Aged 0 through 18 Years; United States, 2019
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/recommended-immunizations-schedule
Tipranavir
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/tipranavir
Appendix B: Mycobacterium avium Complex
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/appendix-b-10
What’s New in the Guidelines
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new
Baseline Evaluation
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/baseline-evaluation
Drug-Drug Interactions: Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-drug-interactions-non-nucleoside
Overview
https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/overview-2
Drug-Drug Interactions: Integrase Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors or Protease Inhibitors
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-drug-interactions-integrase
Pagination
First page
«
Previous page
‹
…
Page
165
Page
166
Page
167
Page
168
Current page
169
Page
170
Page
171
Page
172
Page
173
…
Next page
›
Last page
»